Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates

Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates

Medical management of ulcerative colitis has continued to evolve over more than half of a century. Perhaps, the important advance was the development of sulfasalazine, a drug initially used for the treatment of inflammatory joint disease and only later in the treatment of inflammatory bowel disease. Sulfasalazine was a combination designer drug consisting of sulfapyridine, a sulfa-containing an...

Medical management of ulcerative colitis.

Ulcerative colitis (UC) is a chronic and relapsing inflammation limited to the colonic mucosa and always involving the rectum with variable extension towards the cecum. The aim of medical treatment is to induce and maintain clinical remission. In contrast to Crohn's disease for which a 'top-down' or 'early aggressive' therapy is discussed, in UC the concept of a step-up treatment is still valid...

Ulcerative Colitis-Associated Colorectal Cancer Prevention by 5-Aminosalicylates: Current Status and Perspectives

5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis

BACKGROUND Although the chemopreventive effect of 5-aminosalicylates on patients with ulcerative colitis has been extensively studied, the results remain controversial. This updated review included more recent studies and evaluated the effectiveness of 5-aminosalicylates use on colorectal neoplasia prevention in patients with ulcerative colitis. METHODS Up to July 2013, we searched Medline, E...

update on the management of ulcerative colitis

the present treatment goals for inflammatory bowel diseases (ibd) especially ulcerative colitis (uc) include rapid induction of clinical remission, steroid-free maintenance of clinical remission, mucosal healing and improvement of quality of life in uc patients. immunomodulators have been reserved for steroid- dependent or steroid- refractory uc patients. among these agents, azathioprine/6-merc...